Clinical Trials
26 trialsNCT02075840 2026-05-29
ALEX
Hoffmann-La Roche
Phase 3 Completed
NCT03409614 2026-05-18
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Regeneron Pharmaceuticals
Phase 3 Completed
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT04484142 2026-03-24
Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)
Daiichi Sankyo
Phase 2 Completed
NCT02504372 2026-03-17
PEARLS
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03088540 2026-02-23
Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)
Regeneron Pharmaceuticals
Phase 3 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT03215706 2025-12-17
CheckMate 9LA
Bristol-Myers Squibb
Phase 3 Completed
NCT03735121 2025-12-05
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02477826 2025-10-30
CheckMate 227
Bristol-Myers Squibb
Phase 3 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT01828099 2025-01-16
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
Novartis
Phase 3 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01970865 2024-08-12
A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations
Pfizer
Phase 1/2 Completed
NCT02414139 2024-03-20
Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)
Novartis
Phase 2 Completed
NCT01774721 2023-11-14
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
Pfizer
Phase 3 Completed
NCT02125461 2023-10-10
PACIFIC
AstraZeneca
Phase 3 Completed
NCT02220894 2023-10-10
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01336634 2022-04-04
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Novartis
Phase 2 Completed
NCT02737501 2021-08-20
ALTA-1L
Takeda
Phase 3 Completed
NCT01631552 2021-08-12
Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer
Gilead Sciences
Phase 1/2 Completed
NCT01121393 2018-12-14
BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)
Boehringer Ingelheim
Phase 3 Completed
NCT00949650 2018-04-06
BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation
Boehringer Ingelheim
Phase 3 Completed
NCT00525148 2016-09-16
LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations
Boehringer Ingelheim
Phase 2 Completed